Sources | Names Used |
---|---|
CTRPv2 | tanespimycin:bortezomib (250:1 mol/mol) |
PharmacoGx | tanespimycin:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ZER1 | CTRPv2 | pan-cancer | AAC | -0.17 | 9e-06 |
mRNA | PYURF | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-06 |
mRNA | RABIF | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-06 |
mRNA | EXOSC8 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-05 |
mRNA | LAMA5 | CTRPv2 | pan-cancer | AAC | -0.19 | 1e-05 |
mRNA | PRIMPOL | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
mRNA | CREBRF | CTRPv2 | pan-cancer | AAC | -0.16 | 1e-05 |
mRNA | LTV1 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
mRNA | PIGY | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
mRNA | DTL | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-05 |